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The novel coronavirus severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) is the cause of COVID-19. The main receptor of
SARS-CoV-2, angiotensin I converting enzyme 2 (ACE2), is now un-
dergoing extensive scrutiny to understand the routes of transmission
and sensitivity in different species. Here, we utilized a unique dataset
of ACE2 sequences from 410 vertebrate species, including 252 mam-
mals, to study the conservation of ACE2 and its potential to be used
as a receptor by SARS-CoV-2. We designed a five-category binding
score based on the conservation properties of 25 amino acids impor-
tant for the binding between ACE2 and the SARS-CoV-2 spike pro-
tein. Only mammals fell into the medium to very high categories and
only catarrhine primates into the very high category, suggesting that
they are at high risk for SARS-CoV-2 infection. We employed a pro-
tein structural analysis to qualitatively assess whether amino acid
changes at variable residues would be likely to disrupt ACE2/
SARS-CoV-2 spike protein binding and found the number of pre-
dicted unfavorable changes significantly correlated with the binding
score. Extending this analysis to human population data, we found
only rare (frequency <0.001) variants in 10/25 binding sites. In addi-
tion, we found significant signals of selection and accelerated evo-
lution in the ACE2 coding sequence across all mammals, and specific
to the bat lineage. Our results, if confirmed by additional experimen-
tal data, may lead to the identification of intermediate host species
for SARS-CoV-2, guide the selection of animal models of COVID-19,
and assist the conservation of animals both in native habitats and in
human care.
SARS-CoV-2 | COVID-19 | ACE2 | comparative genomics | species
conservation
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, a major pandemic that threatens
millions of lives and the global economy (1). Comparative analysis
of SARS-CoV-2 and related coronavirus sequences has shown
that SARS-CoV and SARS-CoV-2 likely had ancestors that
originated in bats, followed by transmission to an intermediate
host, and that both viruses may have an extended host range that
includes primates and other mammals (1–3). Many mammalian
species host coronaviruses and these infections are frequently as-
sociated with severe clinical diseases, such as respiratory and en-
teric disease in pigs and cattle (4, 5). Molecular phylogenetics
revealed that at least one human coronavirus (HCov-OC43) may
have originated in cattle or swine and that this virus was associated
with a human pandemic that emerged in the late 19th century (6).
Recent data indicate that coronaviruses can be transmitted from
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bats to other wildlife species and humans (7), and from humans to
tigers (8) and pigs (9). Therefore, understanding the host range of
SARS-CoV-2 and related coronaviruses is essential for improving
our ability to predict and control future pandemics. It is also
crucial for protecting populations of wildlife species in native
habitats and under human care, particularly nonhuman primates,
which may be susceptible to COVID-19 (10).
The angiotensin I converting enzyme 2 (ACE2) serves as a
functional receptor for the spike protein (S) of SARS-CoV and
SARS-CoV-2 (11, 12). Under normal physiological conditions,
ACE2 is a dipeptidyl carboxypeptidase that catalyzes the con-
version of angiotensin I into angiotensin 1-9, a peptide of un-
known function (13). ACE2 also converts angiotensin II, a
vasoconstrictor, into angiotensin 1-7, a vasodilator that affects
the cardiovascular system (13) and may regulate other compo-
nents of the renin–angiotensin system (14). The host range of
SARS-CoV-2 may be extremely broad due to the conservation of
ACE2 in mammals (2, 12). While SARS-CoV-2 and related
coronaviruses use human ACE2 as a primary receptor, corona-
viruses may use other proteases as receptors, such as CD26
(DPP4) for Middle East Respiratory Syndrome (MERS)-CoV
(15), thus limiting or extending host range.
In humans, ACE2 may be a cell membrane protein or it may
be secreted (13). The secreted form is created primarily by en-
zymatic cleavage of surface-bound ACE2 by ADAM17 and other
proteases (13). ACE2 maps to the human X chromosome. Many
synonymous and nonsynonymous mutations have been identified
in this gene, although most of these are rare at the population
level (16), and few are believed to affect cellular susceptibility to
human coronavirus infections (17). Site-directed mutagenesis
and coprecipitation of SARS-CoV constructs have revealed
critical residues on the ACE2 tertiary structure that are essential
for binding to the virus receptor-binding domain (RBD) (18).
These findings are supported by the cocrystallization and struc-
tural determination of the SARS-CoV and SARS-CoV-2 S
proteins with human ACE2 (12, 19, 20), as well as binding af-
finity with nonhuman ACE2 (18). Coronaviruses may adapt to
new hosts in part through mutations in S that enhance binding
affinity for ACE2. The best-studied example is the evolution of
SARS-CoV-like coronaviruses in the masked palm civet, which is
believed to be the intermediate host for transmission of a
SARS-CoV-like virus from bats to humans (2). The masked palm
civet SARS-CoV S acquired two mutations that increased its
affinity for human ACE2 (2). An intermediate host for
SARS-CoV-2 has not been identified definitively, although the
Malayan pangolin has been proposed (21).
Comparative analysis of ACE2 protein sequences can be used
to predict their ability to bind SARS-CoV-2 S (2) and therefore
may yield important insights into the biology and potential
zoonotic transmission of SARS-CoV-2 infection. Recent work
predicted ACE2/SARS-CoV-2 S-binding affinity in some verte-
brate species, but phylogenetic sampling was extremely limited
(10, 22). Here, we used a combination of comparative genomic
approaches and protein structural analysis to assess the potential
of ACE2 homologs from 410 vertebrate species (including rep-
resentatives from all vertebrate classes: fishes, amphibians, birds,
reptiles, and mammals) to serve as a receptor for SARS-CoV-2
and to understand the evolution of ACE2/SARS-CoV-2 S-binding
sites. Our results reinforce earlier findings on the natural host
range of SARS-CoV-2 and predict a broader group of species that
may serve as a reservoir or intermediate host(s) for this virus.
Importantly, many threatened and endangered species were found
to be at potential risk for SARS-CoV-2 infection based on their
ACE2 binding score, suggesting that as the pandemic spreads
humans could inadvertently introduce a potentially devastating
new threat to these already vulnerable populations, especially the
great apes and other primates.
Results
Comparison of Vertebrate ACE2 Sequences and Their Predicted Ability
to Bind SARS-CoV-2. We identified 410 unique vertebrate species
with ACE2 orthologs (Dataset S1), including representatives of all
vertebrate taxonomic classes. Among these were 252 mammals, 72
birds, 65 fishes, 17 reptiles, and 4 amphibians. Twenty-five amino
acids corresponding to known SARS-CoV-2 S-binding residues
(10, 12, 20) were examined for their similarity to the residues in
human ACE2 (Figs. 1 and 2 and Dataset S1). On the basis of
known interactions between specific residues on ACE2 and the
RBD of SARS-CoV-2 S, a set of rules was developed for pre-
dicting the propensity for S binding to ACE2 from each species
(Materials and Methods). Five score categories were predicted:
very high, high, medium, low, and very low. Results for all species
are shown in Dataset S1, and results for mammals only are shown
in Figs. 1 and 2. The very high classification had at least 23/25
ACE2 residues identical to human ACE2 and other constraints at
SARS-CoV-2 S-binding hot spots (Materials and Methods). The 18
species predicted as very high were all Old-World primates and
great apes with ACE2 proteins identical to human ACE2 across
all 25 binding residues. The ACE2 proteins of 28 species were
classified as having a high propensity for binding the SARS
-CoV-2 S RBD. Among them are 12 cetaceans (whales and dol-
phins), 7 rodents, 3 cervids (deer), 3 lemuriform primates, 2 rep-
resentatives of the order Pilosa (giant anteater and southern
tamandua), and 1 Old-World primate (Angola colobus; Fig. 1).
Fifty-seven species scored as medium for the propensity of their
ACE2 to bind SARS-CoV-2 S. This category has at least 20/25
residues identical to human ACE2 but more relaxed constraints
for critical binding residues. All species with medium score are
mammals distributed across six orders.
Among Carnivora, 9/43 scored medium, 9/43 scored low, and
25/43 scored very low (Figs. 1 and 2). The carnivores scoring
medium were exclusively felids, including the domestic cat and
Siberian tiger. Among the 13 primate species scoring medium,
there were 10 New-World primates and three lemurs. Of 45 ro-
dent species, 11 scored medium. Twenty-one of 30 artiodactyls
scored medium, including several important wild and domesti-
cated ruminants, such as domesticated cattle, bison, sheep, goat,
water buffalo, Masai giraffe, and Tibetan antelope. Species scoring
medium also included two of three lagomorphs and one cetacean.
All chiropterans (bats) scored low (n = 8) or very low (n = 29;
Fig. 2), including the Chinese rufous horseshoe bat, from which a
coronavirus (SARSr-CoV ZC45) related to SARS-CoV-2 was
identified (1). Only 7.7% (3/39) primate species’ ACE2 scored
low or very low, and 61% of rodent species scored low (10/46) or
very low (18/46). All monotremes (n = 1) and marsupials (n = 4),
birds (n = 72), fish (n = 65), amphibians (n = 4), and reptiles
(n = 17) scored very low, with fewer than 18/25 ACE2 residues
identical to the human and many nonconservative amino acid
substitutions at the remaining nonidentical sites (Dataset S1).
Notable species scoring very low include the Chinese pangolin,
Sunda pangolin, and white-bellied pangolin (Fig. 2 and
Dataset S1).
Structural Analysis of the ACE2/SARS-CoV-2 S-Binding Interface. We
complemented the sequence identity-based scoring scheme with
a qualitative structure-based scoring system. Our approach was
to take the 55 variants of individual residues observed in the
ACE2 binding interface, excluding glycosylation sites, from 28
representative species, and identify the best-fit rotamer for each
variant when modeled onto the human crystal structure 6MOJ
(12). Each variant was then assigned to one of three groups:
neutral (likely to maintain similar contacts; 18 substitutions),
weaken (likely to weaken the interaction; 14 substitutions), or
unfavorable (likely to introduce unfavorable interactions; 23 sub-
stitutions; SI Appendix, Fig. S1). Variations of residue S19 were









































Fig. 1. Cross-species conservation of ACE2 at the known binding residues and predictions of SARS-CoV-2 S-binding propensity. Species are sorted by binding
scores. The ID column depicts the number of amino acids identical to human binding residues. Bold amino acid positions (also labeled with asterisks) represent
residues at binding hot spots and constrained in the scoring scheme. Each amino acid substitution is colored according to its classification as nonconservative
(orange), semiconservative (yellow), or conservative (blue), as compared to the human residue. Bold species names depict species with threatened IUCN risk
status. The 410 vertebrate species dataset is available in Dataset S1.















































excluded because of conflicting results between the two structures
of the human ACE2/SARS-CoV-2 S protein complexes 6MOJ
and 6VW1 at this site (the two structures were in agreement for all
other residues at the binding interface). The structural binding
assessments complement the sequence identity analysis, with the
fraction of residues ranked as unfavorable correlating very strongly
with the substitution scoring scheme (Spearman correlation rho =
0.76; P < 2.2e-16; Fig. 3). To check for easily identifiable gross
Fig. 2. Cross-species conservation of ACE2 at the known binding residues and predictions of SARS-CoV-2 S-binding propensity. Species are sorted by binding
scores. The ID column depicts the number of amino acids identical to human binding residues. Bold amino acid positions (also labeled with asterisks) represent
residues at binding hot spots and constrained in the scoring scheme. Each amino acid substitution is colored according to its classification as nonconservative
(orange), semiconservative (yellow), or conservative (blue), as compared to the human residue. Bold species names depict species with threatened IUCN risk
status. The 410 vertebrate species dataset is available in Dataset S1.









































conformational changes between ACE2 proteins of different spe-
cies that could potentially cause misinterpretation of the ACE2/
SARS-CoV-2 S interface, we also generated homology models of
ACE2 from the 28 representative species and compared them to
the human structures. All models showed high similarity to the
human protein along the C⍺ backbone (SI Appendix, Fig. S2) with
an rmsd range of 0.06 to 0.17. Among all 28 structures, high cov-
erage ranging from 91 to 99% and high global model quality esti-
mation ranging between 0.82 and 0.89 (SI Appendix, Table S1), as
assessed in CHIMERA, indicated a lack of major conformational
changes between species and supported the validity of using human
structures as a template for modeling variants of ACE2 interface
residues across species.
Structural Analysis of Variation in Human ACE2. We examined the
variation in ACE2 binding residues within humans, some of
which have been proposed to alter binding affinity (17, 23–26).
We integrated data from six different sources, dbSNP, 1KGP,
Topmed, UK10K, gnomAD, and CHINAMAP, and identified a
total of 11 variants in 10 of the 25 ACE2 binding residues
(Dataset S2). All variants found are rare, with allele frequency
(f) < 0.01 in any individual population and f < 0.0007 across all
populations. Three of the 11 single-nucleotide variants were si-
lent, leading to synonymous amino acid changes, seven were
missense variants resulting in conservative amino acid substitu-
tions, and one, S19P, resulted in a semiconservative substitution.
S19P has the highest allele frequency of the 11 variants, with f =
0.0003 across all populations (16). We evaluated, by structural
homology, six missense variants. Four were neutral and two
weakening (E35K, f = 0.000016; E35D, f = 0.000279799). S19P
was not included in our structural homology assessment, but a
recent study predicted it would increase ACE2/SARS-CoV-2
binding affinity (27). Thus, with an estimated summed frequency
of 0.001 (maximum of 0.004 in any single population), genetic
variation in the human ACE2/SARS-CoV-2 S-binding interface
is rare overall, and it is unclear whether the existing variation
increases or decreases susceptibility to infection.
Evolution of ACE2 across Mammals. We next investigated the evo-
lution of ACE2 variation in vertebrates, including how patterns
of positive selection compare between bats, a mammalian line-
age that harbors a high diversity of coronaviruses (28), and other
mammalian clades. We first inferred the phylogeny of ACE2
using our 410-vertebrate alignment and IQTREE, using the best-
fit model of sequence evolution (JTT+F + R7) and rooting the
topology on fishes (Dataset S3 and SI Appendix, Fig. S3). We
then assayed sequence conservation with phyloP. The majority of
ACE2 codons are significantly conserved across vertebrates and
across mammals (Dataset S4.1), likely reflecting its critical
function in the renin–angiotensin system (29). Ten residues in
the ACE2 binding domain are exceptionally conserved in Chi-
roptera and/or Rodentia (Dataset S4.2).
We next used phyloP and CodeML to test for accelerated
sequence evolution and positive selection, respectively. PhyloP
compares the rate of evolution at each codon to the expected
rate in a model estimated from third nucleotide positions of the
codon and is agnostic to synonymous versus nonsynonymous
substitutions (dN/dS). CodeML uses ⍵ = dN/dS > 1 and Bayes
empirical Bayes (BEB) scores to identify codons under positive
selection and was run on a subset of 64 representative mammals
(Materials and Methods). In this way, PhyloP identifies residues
evolving at a rate higher than the estimated neutral rate of
evolution. In addition, CodeML identifies residues exhibiting an
excess of nonsynonymous over synonymous substitutions.
ACE2 shows significant evidence of positive selection across
mammals (⍵ = 1.83, likelihood ratio test [LRT] = 194.13, P <
0.001; Datasets S4.3 and S4.4). Almost 10% of codons (n = 73; 9
near the binding interface) are accelerated within mammals
(Datasets S4.1 and S4.5), and 18 of these have BEB scores greater
than 0.95, indicating positively selected residues (Datasets S4.5
and S4.6 and SI Appendix, Fig. S4). Nineteen accelerated residues,
including two positively selected codons (Q24 and H34), are
known to interact with SARS-CoV-2 S (Fig. 4 A and B, Dataset
S4.5, and SI Appendix, Fig. S5). Q24 has not been observed to be
polymorphic within the human population, and H34 harbors a
synonymous polymorphism (f = 0.00063) but no nonsynonymous
polymorphisms (Dataset S2).
This pattern of acceleration and positive selection in ACE2
also holds for individual mammalian lineages. Using CodeML,
positive selection was detected within the orders Chiroptera
(LRT = 346.40, ⍵ = 3.44, P < 0.001), Cetartiodactyla (LRT =
92.86, ⍵ = 3.83, P < 0.001), Carnivora (LRT = 65.66, ⍵ = 2.27,
P < 0.001), Primates (LRT = 72.33, ⍵ = 3.16, P < 0.001), and
Rodentia (LRT = 91.26, ⍵ = 1.77, P < 0.001). Overall, bats had
more positively selected sites with significant BEB scores (29
sites in Chiroptera compared to 10, 8, 7, and 15 sites in Cetar-
tiodactyla, Carnivora, Primates, and Rodentia, respectively).
Positive selection was found at multiple ACE2/SARS
-CoV-2 S-binding residues in the bat-specific alignment. Pa-
rameters inferred by CodeML were consistent across different
models of evolution (Dataset S4.6). PhyloP was used to assess
shifts in the evolutionary rate within mammalian lineages, for
each assessing signal relative to a neutral model trained on
species from the specified lineage (Datasets S4.7–S4.12 and SI
Appendix, Fig. S6). We discovered six binding residues that are
accelerated in one or more of Chiroptera, Rodentia, or Car-
nivora, five of which also showed evidence for positive selection;
G354 was accelerated in all of these lineages (Dataset S4.13).
Given pervasive signatures of adaptive evolution in ACE2
across mammals, we next sought to test if ACE2 in any mam-
malian lineages is evolving particularly rapidly compared to the
others. CodeML branch-site tests identified positive selection in
both the ancestral Chiroptera branch (one amino acid, ⍵ = 26.7,
LRT = 4.22, P = 0.039) and ancestral Cetartiodactyla branch
(two amino acids, ⍵ = 10.38, LRT = 7.89, P = 0.004; Dataset S4.3)
using 64 mammals. These residues did not correspond to known




























Fig. 3. Congruence between binding score and the structural homology analysis. Species predicted with very high (red) or high binding scores (orange) have
significantly fewer amino acid substitutions rated as potentially altering the binding interface between ACE2 and SARS-CoV-2 using protein structural analysis
when compared to species with low (green) or very low (blue) binding scores. The more severe unfavorable variants are counted on the y axis and less severe
weaken variants on the x axis. Black numerical labels indicate species count.















































positive selection in the ancestral primate, rodent, or carnivore
lineages. PhyloP identified lineage-specific acceleration in Chi-
roptera, Carnivora, Rodentia, Artiodactyla, and Cetacea relative
to mammals (Datasets S4.14–S4.18 and SI Appendix, Fig. S7). The
power to detect acceleration within a clade scaled with the branch
length of the subtree, with rodents having the highest and bats the
second-highest amount of power (SI Appendix, Fig. S8 and Table
S2). Bats have a particularly high level of accelerated evolution (18
codons; P < 0.05). Of these accelerated residues, T27 and M82 are
binding residues for SARS-CoV-2 S, with some bat subgroups
having amino acid substitutions predicted to lead to less fa-
vorable binding of SARS-CoV-2 (Fig. 4 C and D and SI Ap-
pendix, Fig. S1). Surprisingly, a residue that is conserved overall
in our 410 species alignment and in the mammalian subset,
Q728, is perfectly conserved in all 37 species of bats except for
Old-World fruit bat species (Pteropodidae; n = 8), which have a
substitution from Q to E. These results support the theory that
ACE2 is under lineage-specific selective pressures in bats rel-
ative to other mammals.
Positive Selection in SARS-CoV-2 S Protein. Positive selection was
found across 43 viral strains (Dataset S4.19) at sites L455, V483,
and S494 in the SARS-CoV-2 S sequence using CodeML (⍵ =
2.78, LRT = 93.72, P < 0.001). All of these sites lie within or near
the ACE2/SARS-CoV-2 S RBD binding sites (Fig. 4).
Discussion
Phylogenetic analysis of coronaviruses has demonstrated that the
immediate ancestor of SARS-CoV-2 most likely originated in a
bat species (1). However, whether SARS-CoV-2 or the progen-
itor of this virus was transmitted directly to humans or through
an intermediate host is not yet resolved. To identify candidate
intermediate host species and species at risk for SARS-CoV-2
infection, we undertook a deep comparative genomic, evolu-
tionary, and structural analysis of ACE2, which serves as the
SARS-CoV-2 receptor in humans. We drew on the rapidly
growing database of annotated vertebrate genomes, including
new genomes produced by the Genomes 10K-affiliated Bat1K
Consortium, Zoonomia, and Vertebrate Genomes Project, and
other sources (30, 31). We conducted a phylogenetic analysis of
ACE2 orthologs from 410 vertebrate species and predicted their
propensity to bind the SARS-CoV-2 S using a score based on
amino acid substitutions at 25 consensus human ACE2 binding
residues (12, 20). Similarity-based methods are frequently used
for predicting cross-species transmission of viruses (32, 33), in-
cluding SARS-CoV (2). We supported these predictions with
comprehensive structural analysis of the ACE2 binding site
complexed with SARS-CoV-2 S. We also tested the hypothesis
that the ACE2 receptor is under selective constraints in mam-
malian lineages with different susceptibilities to coronaviruses.
We predict that species scoring as very high and high for
propensity of SARS-CoV-2 S binding to ACE2 will have a high
probability of becoming infected by the virus and thus may be
potential intermediate hosts for virus transmission. We also
predict that many species having a medium score have some risk
of infection, and species scored as very low and low are less likely
to be infected by SARS-CoV-2 via the ACE2 receptor. Impor-
tantly, our predictions are based solely on in silico analyses and
must be confirmed by direct experimental data. The prediction
accuracy of the model may be improved in the future as more
extensive data are generated showing the impact of ACE2 mu-
tations on its binding affinity for SARS-CoV-2 S, which may
enable knowledge-based weighting of residues in the scoring
algorithm. Until the present model’s accuracy can be confirmed
with additional experimental data, we urge caution not to over-
interpret the predictions of the present study. This is especially
important with regards to species, endangered or otherwise, in
human care. While species ranked high or medium may be sus-
ceptible to infection based on the features of their ACE2 resi-





























Fig. 4. Residues at the binding interface between ACE2 and SARS-CoV-2 S are under positive selection (CodeML analysis). In the SARS-CoV-2 spike protein
RBD (light teal), this includes three positively selected residues (green, labeled with two asterisks). In ACE2 (wheat-colored, with binding interface residues in
yellow), selected residues occur both outside the binding interface (dark blue) and inside the binding interface (red, labeled with one asterisk). (A) Positively
selected residues in all mammals, including two at the binding interface. (B) A with 90° rotation. (C) Positively selected residues in the Chiroptera lineage,
including five at the binding interface. (D) C with 90° rotation.









































depending on other mechanisms, such as immune response, that
could affect virus replication and spread to target cells, tissues,
and organs. Furthermore, we cannot exclude the possibility that
infection in any species occurs via another cellular receptor (for
a review see ref. 34), as shown for other betacoronaviruses (35),
or lower-affinity interactions with ACE2 as proposed for SARS-
CoV (2). Nonetheless, our predictions provide a useful starting
point for the selection of appropriate animal models for
COVID-19 research and identification of species that may be at
risk for human-to-animal or animal-to-animal transmissions of
SARS-CoV-2.
Several recent studies examined the role of ACE2 in
SARS-CoV-2 binding and cellular infection and its relationship
to experimental and natural infections in different species (26,
35–40). Our study design differs substantially from those in
several aspects: 1) we analyzed a larger number of primates,
carnivores, rodents, cetartiodactyls, and other mammalian orders
and an extensive phylogenetic sampling of fishes, birds, am-
phibians, and reptiles; 2) we analyzed the full set of S-binding
residues across the ACE2 binding site, which was based on a
consensus set from two independent studies (12, 20); 3) we used
different methodologies to assess ACE2 binding capacity for
SARS-CoV-2 S; and 4) our study tested for selection and
accelerated evolution across the entire ACE2 protein. While our
results are consistent with the results and conclusions of Melin
et al. (38) on the predicted susceptibility of primates to
SARS-CoV-2, particularly Old-World primates, we made pre-
dictions for a larger number of primates (n = 39 vs. n = 27), bats
(n = 37 vs. n = 7), other mammals (n = 176 vs. n = 5), and other
vertebrates (n = 158 vs. n = 0). When ACE2 from species in our
study were compared with results of other studies there were
many consistencies, such as the low risk for rodents, but some
predictions differ, such as the relatively high risk predicted by
others for SARS-CoV-2 S binding in pangolin and horse (39),
civet (40), Chinese rufous horseshoe bat (40), and turtles (22).
Our results are generally consistent with a study that tested
binding affinity of soluble ACE2 for the SARS-CoV-2 S RBD
using saturation mutagenesis (27), particularly in the binding
hot-spot region of ACE2 residues 353 to 357 (SI Appendix, Fig.
S1). Importantly, as compared with other studies, our results
greatly expanded the number of candidate intermediate hosts
and identified many additional threatened species that could be
at risk for SARS-CoV-2 infection via their ACE2 receptors.
Evolution of ACE2. Variation in ACE2 in the human population is
rare (16). Overall, ACE2 is intolerant of loss-of-function muta-
tions [pLI = 0.998; LOEUF = 0.25 in gnomAD v2.1.1 (16)]. We
examined a large set of ACE2 variants for their potential dif-
ferences in binding to SARS-CoV-2 S and their relationship to
selected and accelerated sites. We found rare coding variants
that would result in missense mutations causing substitutions in
7/25 binding residues (Dataset S2). Some of those [e.g., E35K,
f = 0.00001636 (16)] could reduce the virus binding affinity as per
our structural analysis (Dataset S2) but would potentially lower
the susceptibility to the virus only in a very small fraction of the
population. Our analysis suggests that some variants (e.g., D38E)
might not affect binding propensity while the potential impact of
others (e.g., S19P) could not be determined. Further investiga-
tions on the effects of these rare variants on ACE2/SARS-CoV-2
binding affinity are needed.
When exploring patterns of codon evolution in ACE2, we
found that multiple ACE2 residues important for the binding of
SARS-CoV-2 S are evolving rapidly across mammals, with two
(Q24 and H34) under positive selection (Fig. 4 A and B and SI
Appendix, Fig. S5). Relative to other lineages analyzed, Chi-
roptera has a greater proportion of accelerated versus conserved
codons (SI Appendix, Fig. S6), particularly in the SARS
-CoV-2 S-binding region, suggesting the possibility of selective
forces on these codons in Chiroptera driven by their interactions
with SARS-CoV-2-like viruses (Fig. 4 C and D and Dataset S4.
13). Indeed, distinct signatures of positive selection found in bat
ACE2 (41) and in the SARS-CoV-2 S protein (42) support the
hypothesis that bats are evolving to tolerate SARS-CoV-2-like
viruses (discussed further below).
Relationship of the ACE2 Binding Score to Known Infectivity of
SARS-CoV-2. Data on susceptibility of nonhuman species to
SARS-CoV-2 is still very limited (SI Appendix, Fig. S10) but
mostly agree with our predictions of ACE2 binding propensity
for SARS-CoV-2 S (Figs. 1 and 2 and Dataset S1). Five out of six
species with demonstrated susceptibility to SARS-CoV-2 infec-
tion score very high [rhesus macaque (43) and cynomolgus ma-
caque (44)] or medium [domestic cat (45, 46), tiger (8) and
golden hamster (47)]. Both species susceptible to infection but
asymptomatic scored low [dog (45, 48) and Egyptian rousette bat
(49)], and the three species resistant to infection scored either low
[pig (45, 49)] or very low [mallard and red junglefowl (45, 49)].
A discrepancy was observed for ferret, which had a low ACE2
binding score but is susceptible to infection (45, 49–51). Ferrets
may be a special case because of their unique respiratory biology
(52). Ferrets are highly susceptible to upper respiratory tract
infections and serve as models of respiratory diseases. They are
susceptible to many viral diseases, including influenza type A and
type B, canine distemper, and SARS-CoV (53). It has been
proposed that ACE2 receptor distribution does not match the
tropism of SARS-CoV in ferrets, because in ferrets viruses may
use LSECTin receptor(s) to enable or enhance infectivity (52,
54). This may also be true for SARS-CoV-2 because the virus can
potentially be glycosylated at 22 N-linked sites (55). Several
studies have demonstrated SARS-CoV-2 infection in ferrets
through intranasal inoculation of high doses (>105 plaque-
forming units) of tissue-cultured virus, followed by direct or in-
direct transmission to naïve ferrets (45, 49–51). However, ex-
perimental infection via direct inoculation of high concentrations
of tissue-cultured virus does not necessarily indicate infectability
under natural conditions, and clinical signs of infection differed
among studies. These data indicate that experimentally inocu-
lated ferrets may become infected by another mechanism, pos-
sibly via high expression levels of low-affinity ACE2 and/or their
very efficient LSECTin system.
Mammals with Predicted High Risk of SARS-CoV-2 Infection. Of the
19 catarrhine primates analyzed, 18/19 scored very high for
binding of their ACE2 to SARS-CoV-2 S and one scored high
(the Angola colobus); the 18 species scoring very high had 25/25
binding residues identical to human ACE2, including rhesus
macaques, which are known to be infected by SARS-CoV-2 and
develop COVID-19-like clinical symptoms (3, 43). Our analysis
predicts that all Old-World primates are susceptible to infection
by SARS-CoV-2 via ACE2. Thus, many of the 21 primate species
native to China could be a potential reservoir for SARS-CoV-2.
The remaining primate species were scored as high or medium,
with only the gray mouse lemur and the Philippine tarsier scoring
as low.
Although inconsistent with the species phylogeny, and overall
similarity to human ACE2, we found that all three species of
cervid deer and 12/14 cetacean species have high scores for
binding of their ACE2s to SARS-CoV-2 S. There are 18 species
of cervids found in China. While coronavirus sequences have
been found in white-tailed deer (56) and gammacoronaviruses
have been found in beluga whales (57, 58) and bottlenose dol-
phins (59), in which they are associated with respiratory diseases,
the cellular receptor used by these viruses is not known. Studies
of cellular infectivity in these species would provide important
data for validating the prediction model.















































Other Artiodactyls. A relatively large fraction (21/30) of artio-
dactyl mammals were classified with medium score for ACE2
binding to SARS-CoV-2 S. These include many species that are
found in Hubei Province and around the world, such as do-
mesticated cattle, sheep, and goats, as well as many species
commonly found in zoos and wildlife parks (e.g., Masai giraffe,
okapi, hippopotamus, water buffalo, scimitar-horned oryx, and
dama gazelle). Although the cattle-derived MDBK cell line was
shown in one study to be resistant to SARS-CoV-2 in vitro (60),
our predictions suggest that ruminant artiodactyls can serve as a
reservoir for SARS-CoV-2, which would have significant epide-
miological implications as well as implications for food produc-
tion and wildlife management (discussed below). It is noteworthy
that camels and pigs, known for their ability to be infected by
other coronaviruses (28), both score low in our analysis. These
data are consistent with results (discussed above) indicating that
pigs cannot be infected with SARS-CoV-2 either in vivo (45) or
in vitro (60) but inconsistent with transfection studies using pig
ACE2 receptors expressed in HeLa cells (1).
Rodents. Among the rodents, 7/46 species score high for ACE2
binding to SARS-CoV-2 S, and the remaining 11, 10, and 18
score medium, low, or very low, respectively. House mouse
scored very low, consistent with infectivity studies (1, 60). Given
that wild rodent species likely come in contact with bats as well
as with other predicted high-risk species, rodents with high and
medium scores cannot be excluded as possible intermediate
hosts for SARS-CoV-2.
Bats and Other Species of Interest. Chiroptera represents a clade of
mammals that are of high interest in COVID-19 research be-
cause several bat species are known to harbor coronaviruses,
including those most closely related to SARS-CoV-2 (1). We
analyzed ACE2 from 37 bat species, of which 8 and 29 scored
low and very low, respectively. These results were intriguing
because the three Rhinolophus spp. tested, including the Chinese
rufous horseshoe bat, are major suspects in the transmission of
SARS-CoV-2, or a closely related virus, to humans (1). Bats have
been shown to harbor the highest diversity of betacoronaviruses
among mammals (28) and show little pathology in individuals
carrying these viruses (61).
Do bat ACE2 receptors bind SARS-CoV-2 S? Zhou et al. (1)
transfected human ACE2-negative HeLa cells with ACE2 from a
Chinese rufous horseshoe bat and obtained a low-efficiency in-
fection with SARS-CoV-2. A recent report indicates that
SARS-CoV-2 S protein can bind vesicular stomatitis virus (VSV)
pseudotypes expressing halcyon horseshoe bat (Rhinolophus al-
cyone) ACE2 in BHK-21 cells (60). However, cell lines derived
from big brown bat (Eptesicus fuscus) (62), Lander’s horseshoe
bat (Rhinolophus landeri), and Daubenton’s bat (Myotis dau-
bentonii) could not be infected with SARS-CoV-2 (60). Relat-
edly, cell lines from six different species of bats could not be
infected with SARS-CoV, which also uses human ACE2 as a
receptor (63). These data suggest that some bat species have
evolved ACE2 receptors that do not bind SARS-CoV-like viru-
ses or bind them with very low affinity, which is supported by our
results showing positive selection and accelerated evolution of
ACE2 in chiropterans. Alternatively, ACE2 expression could be
very low in the bat cell lines, or SARS-CoV-2-like viruses can use
other receptors, such as the MERS-CoV, a betacoronavirus that
uses CD26/DPP4 (15), and porcine transmissible enteritis virus,
an alphacoronavirus that uses aminopeptidase N (64). Also, other
molecules required for SARS-CoV infection, such as TMPRSS2,
might not be sufficiently expressed or function differently in bats.
Whether an ancestor of SARS-CoV-2, such as RaTG13, uti-
lizes bat ACE2 is an important question related to whether bat
ACE2 receptors bind SARS-CoV-2 S (discussed above).
RaTG13 was found in feces of the intermediate horseshoe bat
(Rhinolophus affinis) (1), but to our knowledge this virus has not
been shown to bind to ACE2 of R. affinis or any other bat spe-
cies. In addition, RaTG13 was reported not to infect human cells
expressing Rhinolophus sinicus ACE2 in a recent study (65).
Relatedly, Hoffman et al. (63) were unable to infect bat kidney-
and lung-derived cell lines derived from six different species with
VSV pseudotypes bearing SARS-CoV S protein or pseudotypes
of two bat SARS-related CoV (Bg08 and Rp3) (63). Lack of
concordance between the presence of bat SARS-CoV-like
coronaviruses and binding to bat ACE2 may arise because of
variations in susceptibility among bat species to SARS-CoV-like
coronaviruses or due to one of the mechanisms discussed above.
Carnivores. Recent reports of a Malayan tiger and a domestic cat
infected by SARS-CoV-2 suggest that the virus can be trans-
mitted to other felids (8, 45). Our results are consistent with
these studies; 9/9 felids we analyzed scored medium for ACE2
binding of SARS-CoV-2 S. However, the masked palm civet, a
member of the Viverridae family that is related to but distinct
from Felidae and proposed as the intermediate host for SARS-
CoV, scored as very low. While our results are inconsistent with
transfection studies using civet ACE2 receptors expressed in
HeLa cells (1), these experiments have limitations as discussed
above, and no data are available on infectivity in civet cells or
animals. While carnivores closely related to dogs (dingoes,
maned wolves, and foxes) all scored low, experimental data
consistently show that dogs are not readily infected or symp-
tomatic (45, 60, 66).
Pangolins. Considerable controversy surrounds reports that pan-
golins can serve as an intermediate host for SARS-CoV-2, with
some reports proposing that SARS-CoV-2 arose as a recombi-
nant between bat and pangolin betacoronaviruses (21, 67), while
another study rejected that claim (68). In our study, ACE2 of
Chinese pangolin, Sunda pangolin, and white-bellied pangolin
had low or very low binding score for SARS-CoV-2 S. Binding of
pangolin ACE2 to SARS-CoV-2 S was predicted using molecular
binding simulations (67); however, neither experimental infec-
tion nor in vitro infection with SARS-CoV-2 has been reported
for pangolins. Further studies are necessary to resolve whether
SARS-CoV2 S binds to pangolin ACE2.
Other Vertebrates. Our analysis of species in 29 orders of fishes,
29 orders of birds, 3 orders of reptiles, and 2 orders of am-
phibians predicts that the ACE2 proteins of species within these
vertebrate classes are not likely to bind SARS-CoV-2 S. Thus,
vertebrate classes other than mammals are not likely to be an
intermediate host or reservoir for the virus, despite predictions
reported in a recent study (39), unless SARS-CoV-2 uses an-
other receptor for infection. With diverse nonmammal verte-
brates sold in the seafood and wildlife markets of Asia and
elsewhere, it is important to determine if SARS-CoV-2 can be
found in nonmammalian vertebrates.
Animal Models for COVID-19. Presently, there is a tremendous need
for animal models to study SARS-CoV-2 infection and patho-
genesis, as the only species currently known to be infected and
show similar symptoms of COVID-19 is rhesus macaque. Non-
human primate models have proven to be highly valuable for
other infectious diseases but are expensive to maintain and
numbers of experimental animals are limited. Our results pro-
vide an extended list of potential animal models for SARS
-CoV-2 infection and pathogenesis, including large animals
maintained for biomedical and agricultural research (e.g., do-
mesticated sheep and cattle), and Chinese hamster and Syrian/
golden hamster (47), which may be preferred due to their easier
handling and already established value as models for other hu-
man diseases caused by viruses (69).









































Relevance to Threatened Species. Among the 103 species that
scored very high, high, and medium for ACE2/SARS-CoV-2 S
binding, 41 (40%) are classified in one of three “threatened”
categories (vulnerable, endangered, and critically endangered) on
the International Union of Conservation of Nature (IUCN) Red
List of Threatened Species, five are classified as near threatened,
and two species are classified as extinct in the wild (70) (Dataset
S1). This represents only a small fraction of the threatened species
potentially susceptible to SARS-CoV-2. For example, all 20 cat-
arrhine primate species in our analysis, representing three families
(Cercopithecidae, Hylobatidae, and Hominidae) scored very high,
suggesting that all 185 species of catarrhine primates, including 62
classified as threatened, are potentially susceptible to SARS
-CoV-2. Similarly, all three species of deer, representatives of a
family of ∼92 species (Cervidae), including 25 classified as
threatened, scored as high. In contrast, some threatened species
scored low or very low, such as the giant panda (low), potentially
positive news for these at-risk populations.
In Cetacea, 12 of 14 species score as high, and of those two are
threatened. Toothed whales have potential for viral outbreaks
and have lost function of a gene that is key to the antiviral re-
sponse in other mammalian lineages (71). If they are susceptible
to SARS-CoV-2, human-to-animal transmission could pose a
risk through sewage outfall (72) and contaminated refuse from
cities, commercial vessels, and cruise liners (73). Our results have
practical implications for populations of threatened species in
the wild and those under human care (including those in zoos).
Established guidelines for minimizing potential human-to
-animal transmission should be implemented and strictly fol-
lowed. Guidelines for field researchers working on great apes
established by the IUCN have been in place since 2015 in re-
sponse to previous human disease outbreaks (74) and have re-
ceived renewed attention because of SARS-CoV-2 (74–76). For
zoos, guidelines in response to SARS-CoV-2 have been distrib-
uted by several taxon advisory groups of the North American
Association of Zoos and Aquariums, the American Association
of Zoo Veterinarians, and the European Association of Zoo and
Wildlife Veterinarians, and these organizations are actively
monitoring and updating knowledge of species in human care
considered to be potentially sensitive to infection (77, 78). Al-
though in silico studies suggest potential susceptibility of diverse
species, verification of infection potential is warranted, using cell
cultures, stem cells, organoids, and other methods that do not
require direct animal infection studies. Zoos and other facilities
that maintain living animal collections are in a position to pro-
vide such samples for generating crucial research resources by
banking tissues and cryobanking viable cell cultures in support of
these efforts.
Materials and Methods
ACE2 Coding and Protein Sequences. All human ACE2 orthologs for vertebrate
species, and their respective coding sequences, were retrieved from NCBI
Protein (20 March 2020) (79). ACE2 coding DNA sequences were extracted
from available or recently sequenced genome assemblies for 123 other
mammalian species, with the help of genome alignments and the human or
within-family ACE2 orthologs. The protein sequences were predicted using
AUGUSTUS v3.3.2 (80) or CESAR v2.0 (81) and the translated protein se-
quences were checked against the human ACE2 ortholog. ACE2 gene pre-
dictions were inspected and manually curated if necessary. For four bat
species (Micronycteris hirsuta, Mormoops blainvillei, Tadarida brasiliensis,
and Pteronotus parnellii) the ACE2 coding region was split into two scaffolds
which were merged, and for Eonycteris spelaea a putative 1-bp frameshift
base error was corrected. Eighty ACE2 protein sequence predictions were
obtained from the Zoonomia project, 19 from the Hiller Lab, 12 from the
Koepfli laboratory, 8 from the Lewin laboratory, and 4 from the Zhao lab-
oratory. The sources and accession numbers for the genomes or proteins
retrieved from NCBI are listed in Dataset S1. The final set of ACE2 coding and
protein sequences originated from 410 vertebrate species. To ensure align-
ment robustness, the full set of coding and protein sequences were aligned
independently using Clustal Omega (82), MUSCLE (83), and COBALT (84), all
with default parameters. All resulting protein alignments were identical.
Clustal Omega alignments were used in the subsequent analysis. The clas-
sification of amino acid substitutions as conservative, semiconservative, and
nonconservative were based on Clustal Omega definitions, which rely on the
Gonnet Pam250 matrix scores. Briefly, a conservative substitution indicates a
change to an amino acid with strongly similar biochemical/physicochemical
properties, a semiconservative substitution depicts a change to an amino
acid with weakly similar properties, and a nonconservative substitution de-
picts a change to an amino acid with no biochemical/physicochemical
similarities.
Identification of ACE2 Residues Involved in Binding to SARS-CoV-2 S Protein.
We identified 22 ACE2 protein residues that were previously reported to be
critical for the effective binding of ACE2 RBD and SARS-CoV-2 S (12, 20).
These residues include S19, Q24, T27, F28, D30, K31, H34, E35, E37, D38, Y41,
Q42, L45, L79, M82, Y83, N330, K353, G354, D355, R357, and R393. All these
residues were identified from the cocrystallization and structural determi-
nation of SARS-CoV-2 S and ACE2 RBD (12, 20). The known human ACE2 RBD
glycosylation sites N53, N90, and N322 were also included in the analyzed
residue set (10).
ACE2 and SARS-CoV-2 Binding Ability Prediction. Based on the known inter-
actions of ACE2 and SARS-CoV-2 residues, we developed a set of rules for
predicting the likelihood of the SARS-CoV-2 S binding to ACE2. These rules
are primarily based on sequence similarity to the human ACE2 binding res-
idues, with targeted rules applied to positions K353, K31, E35, M82, N53,
N90, and N322 based on the effects of amino acid substitution on binding of
SARS-CoV S (19). Sites N53, N90, and N322 are glycosylation sites at which
disruption has been shown to affect viral attachment (10, 19). K353 and K31
are virus-binding hot spots; K353 establishes a salt bridge with ACE2 D38,
and K31 forms a hydrogen bond with SARS-CoV-2 Q493 (12, 20). E35 sup-
ports the K31 binding hot spot by also establishing a hydrogen bond with
SARS-CoV-2 Q493. The disruption of interactions at these residues, as well as
the replacement of M82, were shown to significantly affect the attachment
of SARS-CoV (19). Each species was classified in one of five categories: very
high, high, medium, low, or very low potential for ACE2 binding to
SARS-CoV-2 S. Species in the very high category have at least 23/25 critical
residues identical to the human; have K353, K31, E35, M82, N53, N90, and
N322; and have only conservative amino acid substitutions among the
nonidentical 2/25 residues. Species in the high group have at least 20/25
residues identical to the human; have K353; have only conservative sub-
stitutions at K31 and E35; and can only have one nonconservative amino
acid substitution among the 5/25 nonidentical residues. Species scoring
medium have at least 20/25 residues identical to the human; can only have
conservative substitutions at K353, K31, and E35; and can have up to two
nonconservative amino acid substitutions in the 5/25 nonidentical resi-
dues. Species in the low category have at least 18/25 residues identical to
the human; can only have conservative substitutions at K353; and can
have up to three nonconservative amino acid substitutions on the
remaining 7/25 nonidentical residues. Finally, species in the very low
group have fewer than 18/25 residues identical to the human or have at
least four nonconservative amino acid substitutions in the nonidentical
residues.
Protein Structure Analysis. For 28 representative species, we modeled each
exhibited individual variant onto the human structure 6MOJ (12), in the
program CHIMERA (85), by choosing the rotamer with the least number of
clashes, retaining the most initial hydrogen bonds, and containing the
highest probability of formation as calculated by the CHIMERA program
from the Dunbrack 2010 backbone-dependent rotamer library (SI Appendix,
Fig. S9) (86). The chosen rotamer of the variant amino acid was then eval-
uated in the context of its structural environment and assigned a score based
on the likelihood of interface disruption. “Neutral” was assigned if the
residue maintained a similar environment as the original residue and was
predicted to maintain or in some cases increase affinity. “Weakened” was
assigned if hydrophobic contacts were lost and contacts that appear dis-
ruptive are introduced that are not technically clashes. “Unfavorable” was
assigned if clashes are introduced and/or a hydrogen bond is broken. Po-
tential for gross conformational changes between ACE2 proteins was
checked by individually extracting a representative subset of the 28 species’
ACE2 proteins from the multiway alignment, which was then individually
loaded into SWISS-Model (87) to generate homology-derived models. The
output files were aligned to the template structure 6M18 (88), which is a
cryo-electron microscopy model of the SARS-CoV-2 model. Because the
amino acid sequences for the 28 species contained the transmembrane















































domain, the template 6M18 had the closest similarity relative to ACE2
crystal structures, which only contain the ectodomain. The quality of the
models was assessed in SWISS-Model for coverage, sequence identity and
global model quality estimation. The models were then imported to CHI-
MERA and the rmsd was calculated between the template structure and
each individual model. Additional structural visualizations were generated
in Pymol (89).
Human Variants Analysis. All variants at the 25 residues critical for effective
ACE2 binding to SARS-CoV-2-S (10, 12, 20) were compiled from dbSNP (90),
1KGP (91), Topmed (92), UK10K (93), and CHINAMAP (24). Specific pop-
ulation frequencies were obtained from gnomAD v.2.1.1 (16).
Phylogenetic Reconstruction of the Vertebrate ACE2 Species Tree. The multiple
sequence alignment of 410 ACE2 orthologous protein sequences from mam-
mals, birds, fishes, reptiles, and amphibians was used to generate a gene
tree using the maximum likelihood method of reconstruction, as imple-
mented in IQTREE (94). The best-fit model of sequence evolution was de-
termined using ModelFinder (95) and used to generate the species
phylogeny. A total of 1,000 bootstrap replicates were used to determine
node support using UFBoot (96).
Identifying Sites Undergoing Positive Selection. Signatures of site-specific
positive selection in the ACE2 receptor were explored using CodeML, part of
the Phylogenetic Analysis using Maximum Likelihood (PAML) (97) suite of
software. Given CodeML’s computational complexity, a smaller subset
of mammalian taxa (n = 64; Dataset S1), which included species from all
prediction categories mentioned above, was used for selection analyses. To
calculate likelihood-derived dN/dS rates (⍵), CodeML utilizes both a species
tree and a codon alignment. The species tree for all 64 taxa was calculated
using IQTREE (94) and the inferred best-fit model of sequence evolution
(JTT+F + R4). This gene topology was generally in agreement with the 410
taxa tree; however, bats were now sister taxa to Perissodactyla. Therefore,
all selection analyses were run using both the inferred gene tree and a
modified tree with the position of bats manually modified to reflect the
410 taxa topology. All species trees used were unrooted. A codon align-
ment of the 64 mammals was generated using pal2nal (98) with protein
alignments generated with Clustal Omega (82) and their respective coding
sequences.
Site models M7 (null model) and M8 (alternative model) were used to
identify ACE2 sites undergoing positive selection in mammals. Both M7 and
M8 estimate ⍵ using a beta distribution and 10 rate categories per site with ⍵ ≤
1 (neutral or purifying selection) but with an additional 11th category allow-
ing ⍵ >1 (positive selection) in M8. An LRT calculated as 2*(lnLalt – lnLnull),
comparing the fit of both null and alternative model likelihoods was carried
out, with a P value calculated assuming a χ2 distribution. Sites showing evi-
dence of positive selection were identified by a significant (>0.95) BEB score
and validated by visual inspection of the protein alignment. To explore order-
specific instances of positive selection, separate multiple sequence alignments
and gene trees for Chiroptera (n = 37), Cetartiodactyla (n = 45), Carnivora (n =
44), Rodentia (n = 46), and Primates (n = 39) were also generated and explored
using M7 vs. M8 in CodeML. The M0 model in CodeML was used to explore
consistency across parameters inferred maximum likelihood (e.g., transition/
transversion rates and branch lengths).
In addition to site models, branch-site model A1 (null model) and model A
(alternative model) were also implemented targeting various mammalian
orders, specifically Chiroptera, Cetartiodactyla, Rodentia, and Primates, to
identify lineage-specific positive selection in the ACE2 receptor sequence.
Branch-site Model A1 constrains both the target foreground branch
(Carnivora, Chiroptera, Cetartiodactyla, Rodentia, and Primates) and
background branches to ⍵ ≤ 1, while the alternative Model A allows
positive selection to occur in the foreground branch. Null and alternative
models were compared using LRTs as above, with significant BEB sites
identified.
We also looked for positively selected sites in the viral spike protein,
using coding sequences from 43 SARS-CoV-2, SARS-CoV, and CoV-like viral
strains. Protein and codon alignments were generated as above, with the
viral species tree inferred using the spike alignment generated with Clustal
Omega. Site-test models were applied using CodeML and significant BEB
sites identified.
Analysis for Departure from Neutral Evolutionary Rate in ACE2 with PHAST.
Neutral models were trained on the specified species sets (Dataset S4) using
the REV nucleotide substitution model implemented in phyloFit using an
expectation-maximization algorithm for parameter optimization. The neutral
model fit was based on third-codon positions to approximate the neutral
evolution rate specific to the ACE2 gene, using a 410-species phylogenetic tree
generated by IQTREE as described above and rooted on fishes. The program
phyloP was then used to identify codons undergoing accelerated or conserved
evolution relative to the neutral model using –features to specify codons, –
method LRT –mode CONACC, and –subtree for lineage-specific tests, with P
values thus assigned per codon based on an LRT. P values were corrected for
multiple testing using the Benjamini–Hochberg method (99) and sites with a
corrected P value less than 0.05 were considered significant. PhyloFit and
phyloP are both part of the PHAST package v1.4 (100, 101). In order to assess
the relative power among the various clades, we followed a simulation-based
protocol (99). Using the program phyloBoot from PHAST, we generated 1,000
alignments of length 2,415 nucleotides to match the size of the ACE2 codon
alignment for different subtree scaling factors (e.g., phyloBoot -L 2415 -n
1000 -t tree.nh -l 1.11 -S Chiroptera mammals.CDS-3.mod -a out_root) (100,
101). Lambda represents the scale of the departure from neutral evolution in a
clade, with lambda less than one indicating conservation and greater than one
indicating acceleration. Greater values of lambda indicate greater amounts of
acceleration or effect size and thus require less power to detect. We then ran
phyloP on these alignments with the same parameters as used to test the
ACE2 alignment for each clade and determined the number of accelerated
codons at each value of lambda for each clade (SI Appendix, Fig. S8). The
simulator generates nucleotide (not amino acid) sequences and is therefore
conservative in its estimations of power for acceleration but adequate for
defining relative power between clades. These results are concordant with
the summed branch lengths identified using tree_doctor from PHAST (100,
101) for each clade (SI Appendix, Table S2), which is expected as previous
analyses found power to detect departures from neutral evolution to scale
with subtree length (99).
Data Availability. All accession numbers or genome availability for the 410
species used in this study are listed in Dataset S1. This study made use of ACE2
protein sequences previously available from NCBI protein database (n = 287)
and ACE2 sequences extracted from genomes previously available from NCBI
assembly (n = 106) (102). ACE2 sequences were extracted from the genomes of
Bowhead whale (available at http://alfred.liv.ac.uk/downloads/bowhead_
whale/bowhead_whale_scaffolds.zip), velvety free-tailed bat (available at
https://vgp.github.io/genomeark/Molossus_molossus/), greater mouse-eared
bat (available at https://vgp.github.io/genomeark/Myotis_myotis/), Kuhl’s
pipistrelle (available at https://vgp.github.io/genomeark/Pipistrellus_kuhlii/),
scimitar oryx (available at https://www.dnazoo.org/assemblies/Oryx_dammah),
and white-bellied pangolin (available at https://www.dnazoo.org/assemblies/
Phataginus_tricuspis). The ACE2 sequences of Pratt’s roundleaf bat, Pearson’s
horseshoe bat, greater short-nosed fruit bat, and Indian false vampire were
submitted to NCBI under the accession nos. MT515621–MT515624. The
ACE2 sequences of dama gazelle, Sunda clouded leopard, clouded leopard,
maned wolf, bush dog, European mink, and black-footed ferret were
also submitted to NCBI and are available under the accession nos.
MT560518–MT560524.
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